JW Discloses CARTEYVA Reimbursement Price

Company JW Therapeutics Event Type National Reimbursement Drug List price disclosure (HKEX) Modality Autologous CD19 CAR T Asset CARTEYVA (relmacabtagene autoleucel) Target CD19 Disease Area Large B-cell, follicular and mantle cell lymphoma Summary JW Therapeutics disclosed a RMB288,600 National Reimbursement Drug List price for relmacabtagene…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *